Celiac Disease

Gastroenterology
14
Pipeline Programs
16
Companies
14
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
7
2
5
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

14 companies ranked by most advanced pipeline stage

A
AnokionSwitzerland - Ecublens
3 programs
1
1
1
KAN-101Phase 2
Cohort 1 in Part APhase 1/2
KAN-101Phase 11 trial
Active Trials
NCT04248855CompletedEst. Oct 2021
Cook Medical
Cook MedicalIN - Bloomington
2 programs
1
1
Necator americanusPhase 21 trial
Gluten micro-challengePhase 11 trial
Active Trials
NCT02754609CompletedEst. Oct 2019
NCT00671138CompletedEst. Sep 2009
COUR Pharmaceuticals
2 programs
1
1
TIMP-GLIAPhase 2
TIMP-GLIAPhase 1
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
AMG 714Phase 21 trial
Active Trials
NCT02637141Completed64Est. Mar 2017
Teva
TevaIsrael - Petach Tikva
1 program
1
Larazotide AcetatePhase 21 trial
Active Trials
NCT01396213Completed342Est. Aug 2013
BioLineRx
BioLineRxIsrael - Modi’in
1 program
1
BL-7010Phase 1/21 trial
Active Trials
NCT01990885CompletedEst. Oct 2014
CP
Chugai PharmaJapan - Tokyo
1 program
1
DONQ52Phase 11 trial
Active Trials
NCT05425446Completed56Est. Jan 2025
M&
Merck & Co.RAHWAY, NJ
1 program
1
Gluten powder 4gPhase 11 trial
Active Trials
NCT04054544Completed18Est. Jun 2021
Protagonist Therapeutics
Protagonist TherapeuticsAustralia - Brisbane
1 program
1
PTG-100Phase 11 trial
Active Trials
NCT04524221CompletedEst. Apr 2022
Takeda
TakedaTOKYO, Japan
1 program
1
TIMP-GLIAPhase 11 trial
Active Trials
NCT03486990Completed23Est. Jul 2019
Providence Therapeutics
1 program
Celiac Disease and Unexplained Iron Deficiency in a Primary Care SettingN/A1 trial
Active Trials
NCT02036944TerminatedEst. Jan 2015
Regeneron
RegeneronTARRYTOWN, NY
1 program
Gluten PowderN/A1 trial
Active Trials
NCT04614571Completed24Est. May 2024
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
RifaximinN/A1 trial
Active Trials
NCT01137955CompletedEst. Apr 2008
Verona Pharma
Verona PharmaUK - London
1 program
SCREENING OF CELIAC DISEASE IN SCHOLAR CHILDREN IN ITALYN/A1 trial
Active Trials
NCT04867863CompletedEst. Jun 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AmgenAMG 714
TevaLarazotide Acetate
Cook MedicalNecator americanus
BioLineRxBL-7010
Chugai PharmaDONQ52
Protagonist TherapeuticsPTG-100
Merck & Co.Gluten powder 4g
AnokionKAN-101
TakedaTIMP-GLIA
Cook MedicalGluten micro-challenge
RegeneronGluten Powder
Verona PharmaSCREENING OF CELIAC DISEASE IN SCHOLAR CHILDREN IN ITALY
Providence TherapeuticsCeliac Disease and Unexplained Iron Deficiency in a Primary Care Setting
Bausch HealthRifaximin

Clinical Trials (14)

Total enrollment: 527 patients across 14 trials

NCT02637141AmgenAMG 714

A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease

Start: Apr 2016Est. completion: Mar 201764 patients
Phase 2Completed
NCT01396213TevaLarazotide Acetate

A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

Start: Nov 2011Est. completion: Aug 2013342 patients
Phase 2Completed
NCT00671138Cook MedicalNecator americanus

Inoculating Celiac Disease Patients With the Human Hookworm Necator Americanus: Evaluating Immunity and Gluten-sensitivity

Start: Oct 2007Est. completion: Sep 2009
Phase 2Completed
NCT01990885BioLineRxBL-7010

Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients.

Start: Dec 2013Est. completion: Oct 2014
Phase 1/2Completed
NCT05425446Chugai PharmaDONQ52

Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients

Start: Sep 2022Est. completion: Jan 202556 patients
Phase 1Completed
NCT04524221Protagonist TherapeuticsPTG-100

PTG-100 for Patients With Celiac Disease

Start: Feb 2021Est. completion: Apr 2022
Phase 1Completed
NCT04054544Merck & Co.Gluten powder 4g

Gluten Challenge Study in Celiac Disease Participants (MK-0000-402)

Start: Aug 2020Est. completion: Jun 202118 patients
Phase 1Completed
NCT04248855AnokionKAN-101

Assessment of KAN-101 in Celiac Disease (ACeD)

Start: Jan 2020Est. completion: Oct 2021
Phase 1Completed
NCT03486990TakedaTIMP-GLIA

Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease

Start: Jan 2018Est. completion: Jul 201923 patients
Phase 1Completed
NCT02754609Cook MedicalGluten micro-challenge

Hookworm Therapy for Coeliac Disease

Start: Sep 2016Est. completion: Oct 2019
Phase 1Completed
NCT04614571RegeneronGluten Powder

T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge

Start: Nov 2020Est. completion: May 202424 patients
N/ACompleted
NCT04867863Verona PharmaSCREENING OF CELIAC DISEASE IN SCHOLAR CHILDREN IN ITALY

SCREENING OF CELIAC DISEASE IN SCHOLAR CHILDREN IN ITALY

Start: May 2015Est. completion: Jun 2018
N/ACompleted
NCT02036944Providence TherapeuticsCeliac Disease and Unexplained Iron Deficiency in a Primary Care Setting

Celiac Disease and Unexplained Iron Deficiency in a Primary Care Setting

Start: Mar 2014Est. completion: Jan 2015
N/ATerminated
NCT01137955Bausch HealthRifaximin

Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease

Start: Oct 2006Est. completion: Apr 2008
N/ACompleted

Related Jobs in Gastroenterology

Specialty Representative, Gastroenterology – Minneapolis, Minnesota

AbbVie
Remote
7h ago

Key Account Director, Diagnostics and Research

Tempus
Remote
20h ago
$150K - $200K/yr

Experienced Clin Programmer

Johnson & Johnson
High Wycombe, Buckinghamshire, United Kingdom
20h ago

[Innovative Medicine] Director, Government Affairs and Policy Dept., Integrated Market Access Div.

Johnson & Johnson
Chiyoda, Tokyo, Japan
20h ago

Analyst Accounting

Johnson & Johnson
Suzhou, Jiangsu, China
20h ago

Lead Product Security Engineer

Johnson & Johnson
Danvers, Massachusetts, United States of America
20h ago
$94K - $152K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

16 companies competing in this space

Related Indications

Hepatic Impairment(79)Gastroesophageal Reflux Disease(37)Irritable Bowel Syndrome(29)Gastroesophageal Reflux(27)Liver Transplantation(24)Hepatic Insufficiency(22)Liver Cirrhosis(22)Gastroesophageal Reflux Disease (GERD)(14)Hepatic Encephalopathy(12)Gastrointestinal Tolerance(12)